Across TCGA pan-cancer cohorts, CBS Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CBS data layer compared with 24 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CBS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CBS expression acts as an unfavorable survival marker.
UCEC and SKCM are the cancer types where CBS Mutation most reproducibly stratifies survival.